Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.
The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, which is secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.
Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.
Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and FSH, through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these gonadotropins seen in postmenopausal women.
Parenterally administered medroxyprogesterone acetate (MPA) inhibits gonadotropin production, which in turn prevents follicular maturation and ovulation; although available data indicate that this does not occur when the usually recommended oral dosage is given as single daily doses. MPA may achieve its beneficial effect on the endometrium in part by decreasing nuclear estrogen receptors and suppression of epithelial DNA synthesis in endometrial tissue. Androgenic and anabolic effects of MPA have been noted, but the drug is apparently devoid of significant estrogenic activity.
Currently, there are no pharmacodynamic data known for PREMPRO or PREMPHASE tablets.
Absorption
PREMPRO and PREMPHASE contain a formulation of medroxyprogesterone acetate (MPA) that is immediately released and conjugated estrogens that are slowly released over several hours. Conjugated estrogens are water-soluble and are well-absorbed from the gastrointestinal tract after release from the drug formulation. MPA is well absorbed from the gastrointestinal tract. Table 3 and Table 4 summarize the mean pharmacokinetic parameters for select unconjugated and conjugated estrogens and medroxyprogesterone acetate following administration of PREMPRO to healthy, postmenopausal women.
| DRUG | 2 × 0.625 mg CE/2.5 mg MPA Combination Tablets (n = 54) | 2 × 0.625 mg CE/5 mg MPA Combination Tablets (n = 51) | ||||||
|---|---|---|---|---|---|---|---|---|
| BA* = Baseline adjusted Cmax = peak plasma concentration tmax = time peak concentration occurs t1/2 = apparent terminal-phase disposition half-life (0.693/λz) AUC = total area under the concentration-time curve | ||||||||
PK Parameter | Cmax | tmax | t1/2 | AUC | Cmax | tmax | t1/2 | AUC |
Unconjugated Estrogens | ||||||||
Estrone | 175 | 7.6 | 31.6 | 5358 | 124 | 10 | 62.2 | 6303 |
BA* -Estrone | 159 | 7.6 | 16.9 | 3313 | 104 | 10 | 26.0 | 3136 |
Equilin | 71 | 5.8 | 9.9 | 951 | 54 | 8.9 | 15.5 | 1179 |
PK Parameter | Cmax | tmax | t1/2 | AUC | Cmax | tmax | t1/2 | AUC |
Conjugated Estrogens | ||||||||
Total Estrone | 6.6 | 6.1 | 20.7 | 116 | 6.3 | 9.1 | 23.6 | 151 |
BA* -Total Estrone | 6.4 | 6.1 | 15.4 | 100 | 6.2 | 9.1 | 20.6 | 139 |
Total Equilin | 5.1 | 4.6 | 11.4 | 50 | 4.2 | 7.0 | 17.2 | 72 |
PK Parameter | Cmax | tmax | t1/2 | AUC | Cmax | tmax | t1/2 | AUC |
Medroxyprogesterone Acetate | ||||||||
MPA | 1.5 | 2.8 | 37.6 | 37 | 4.8 | 2.4 | 46.3 | 102 |
| DRUG | 4 × 0.45 mg CE/1.5 mg MPA Combination (n = 65) | |||
|---|---|---|---|---|
| BA* = Baseline adjusted Cmax = peak plasma concentration tmax = time peak concentration occurs t1/2 = apparent terminal-phase disposition half-life (0.693/λz) AUC = total area under the concentration-time curve | ||||
PK Parameter | Cmax | tmax | t1/2 | AUC |
Unconjugated Estrogens | ||||
Estrone | 149 | 8.9 | 37.5 | 6641 |
BA* -Estrone | 130 | 8.9 | 21.2 | 3799 |
Equilin | 83 | 8.3 | 15.9 | 1889 |
PK Parameter | Cmax | tmax | t1/2 | AUC |
Conjugated Estrogens | ||||
Total Estrone | 5.4 | 7.9 | 22.4 | 119 |
BA* -Total Estrone | 5.2 | 7.9 | 15.1 | 100 |
Total Equilin | 4.3 | 6.5 | 11.6 | 74 |
PK Parameter | Cmax | tmax | t1/2 | AUC |
Medroxyprogesterone Acetate | ||||
MPA | 0.7 | 2.0 | 26.2 | 5.0 |
Food-Effect: Single dose studies in healthy, postmenopausal women were conducted to investigate any potential drug interaction when PREMPRO or PREMPHASE is administered with a high-fat breakfast. Administration with food decreased the Cmax of total estrone by 18 to 34 percent and increased total equilin Cmax by 38 percent compared to the fasting state, with no other effect on the rate or extent of absorption of other conjugated or unconjugated estrogens. Administration with food approximately doubles MPA Cmax and increases MPA AUC by approximately 20 to 30 percent.
Dose Proportionality: The Cmax and AUC values for MPA observed in two separate pharmacokinetic studies conducted with 2 PREMPRO 0.625 mg/2.5 mg or 2 PREMPRO or PREMPHASE 0.625 mg/5 mg tablets exhibited nonlinear dose proportionality; doubling the MPA dose from 2 × 2.5 to 2 × 5 mg increased the mean Cmax and AUC by 3.2- and 2.8-fold, respectively.
The dose proportionality of estrogens and medroxyprogesterone acetate was assessed by combining pharmacokinetic data across another two studies totaling 61 healthy, postmenopausal women. Single conjugated estrogens doses of 2 × 0.3 mg, 2 × 0.45 mg, or 2 × 0.625 mg were administered either alone or in combination with medroxyprogesterone acetate doses of 2 × 1.5 mg or 2 × 2.5 mg. Most of the estrogen components demonstrated dose proportionality; however, several estrogen components did not. Medroxyprogesterone acetate pharmacokinetic parameters increased in a dose-proportional manner.
Distribution
The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to SHBG and albumin. MPA is approximately 90 percent bound to plasma proteins, but does not bind to SHBG.
Metabolism
Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant portion of the circulating estrogens exists as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Metabolism and elimination of MPA occur primarily in the liver via hydroxylation, with subsequent conjugation and elimination in the urine.
Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.
The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, which is secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.
Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.
Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and FSH, through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these gonadotropins seen in postmenopausal women.
Parenterally administered medroxyprogesterone acetate (MPA) inhibits gonadotropin production, which in turn prevents follicular maturation and ovulation; although available data indicate that this does not occur when the usually recommended oral dosage is given as single daily doses. MPA may achieve its beneficial effect on the endometrium in part by decreasing nuclear estrogen receptors and suppression of epithelial DNA synthesis in endometrial tissue. Androgenic and anabolic effects of MPA have been noted, but the drug is apparently devoid of significant estrogenic activity.
Currently, there are no pharmacodynamic data known for PREMPRO or PREMPHASE tablets.
Absorption
PREMPRO and PREMPHASE contain a formulation of medroxyprogesterone acetate (MPA) that is immediately released and conjugated estrogens that are slowly released over several hours. Conjugated estrogens are water-soluble and are well-absorbed from the gastrointestinal tract after release from the drug formulation. MPA is well absorbed from the gastrointestinal tract. Table 3 and Table 4 summarize the mean pharmacokinetic parameters for select unconjugated and conjugated estrogens and medroxyprogesterone acetate following administration of PREMPRO to healthy, postmenopausal women.
| DRUG | 2 × 0.625 mg CE/2.5 mg MPA Combination Tablets (n = 54) | 2 × 0.625 mg CE/5 mg MPA Combination Tablets (n = 51) | ||||||
|---|---|---|---|---|---|---|---|---|
| BA* = Baseline adjusted Cmax = peak plasma concentration tmax = time peak concentration occurs t1/2 = apparent terminal-phase disposition half-life (0.693/λz) AUC = total area under the concentration-time curve | ||||||||
PK Parameter | Cmax | tmax | t1/2 | AUC | Cmax | tmax | t1/2 | AUC |
Unconjugated Estrogens | ||||||||
Estrone | 175 | 7.6 | 31.6 | 5358 | 124 | 10 | 62.2 | 6303 |
BA* -Estrone | 159 | 7.6 | 16.9 | 3313 | 104 | 10 | 26.0 | 3136 |
Equilin | 71 | 5.8 | 9.9 | 951 | 54 | 8.9 | 15.5 | 1179 |
PK Parameter | Cmax | tmax | t1/2 | AUC | Cmax | tmax | t1/2 | AUC |
Conjugated Estrogens | ||||||||
Total Estrone | 6.6 | 6.1 | 20.7 | 116 | 6.3 | 9.1 | 23.6 | 151 |
BA* -Total Estrone | 6.4 | 6.1 | 15.4 | 100 | 6.2 | 9.1 | 20.6 | 139 |
Total Equilin | 5.1 | 4.6 | 11.4 | 50 | 4.2 | 7.0 | 17.2 | 72 |
PK Parameter | Cmax | tmax | t1/2 | AUC | Cmax | tmax | t1/2 | AUC |
Medroxyprogesterone Acetate | ||||||||
MPA | 1.5 | 2.8 | 37.6 | 37 | 4.8 | 2.4 | 46.3 | 102 |
| DRUG | 4 × 0.45 mg CE/1.5 mg MPA Combination (n = 65) | |||
|---|---|---|---|---|
| BA* = Baseline adjusted Cmax = peak plasma concentration tmax = time peak concentration occurs t1/2 = apparent terminal-phase disposition half-life (0.693/λz) AUC = total area under the concentration-time curve | ||||
PK Parameter | Cmax | tmax | t1/2 | AUC |
Unconjugated Estrogens | ||||
Estrone | 149 | 8.9 | 37.5 | 6641 |
BA* -Estrone | 130 | 8.9 | 21.2 | 3799 |
Equilin | 83 | 8.3 | 15.9 | 1889 |
PK Parameter | Cmax | tmax | t1/2 | AUC |
Conjugated Estrogens | ||||
Total Estrone | 5.4 | 7.9 | 22.4 | 119 |
BA* -Total Estrone | 5.2 | 7.9 | 15.1 | 100 |
Total Equilin | 4.3 | 6.5 | 11.6 | 74 |
PK Parameter | Cmax | tmax | t1/2 | AUC |
Medroxyprogesterone Acetate | ||||
MPA | 0.7 | 2.0 | 26.2 | 5.0 |
Food-Effect: Single dose studies in healthy, postmenopausal women were conducted to investigate any potential drug interaction when PREMPRO or PREMPHASE is administered with a high-fat breakfast. Administration with food decreased the Cmax of total estrone by 18 to 34 percent and increased total equilin Cmax by 38 percent compared to the fasting state, with no other effect on the rate or extent of absorption of other conjugated or unconjugated estrogens. Administration with food approximately doubles MPA Cmax and increases MPA AUC by approximately 20 to 30 percent.
Dose Proportionality: The Cmax and AUC values for MPA observed in two separate pharmacokinetic studies conducted with 2 PREMPRO 0.625 mg/2.5 mg or 2 PREMPRO or PREMPHASE 0.625 mg/5 mg tablets exhibited nonlinear dose proportionality; doubling the MPA dose from 2 × 2.5 to 2 × 5 mg increased the mean Cmax and AUC by 3.2- and 2.8-fold, respectively.
The dose proportionality of estrogens and medroxyprogesterone acetate was assessed by combining pharmacokinetic data across another two studies totaling 61 healthy, postmenopausal women. Single conjugated estrogens doses of 2 × 0.3 mg, 2 × 0.45 mg, or 2 × 0.625 mg were administered either alone or in combination with medroxyprogesterone acetate doses of 2 × 1.5 mg or 2 × 2.5 mg. Most of the estrogen components demonstrated dose proportionality; however, several estrogen components did not. Medroxyprogesterone acetate pharmacokinetic parameters increased in a dose-proportional manner.
Distribution
The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to SHBG and albumin. MPA is approximately 90 percent bound to plasma proteins, but does not bind to SHBG.
Metabolism
Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant portion of the circulating estrogens exists as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Metabolism and elimination of MPA occur primarily in the liver via hydroxylation, with subsequent conjugation and elimination in the urine.
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5Pm ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.